The Science Behind
Scientific Background
The regenerative capacity of the human body relies on a highly organized biological signaling system.
Cells communicate through a constant exchange of biochemical messages, enabling damaged tissues to initiate repair, regulate inflammation, and restore function.
Among these signaling mediators, exosomes — nanosized extracellular vesicles (30–150 nm) — have emerged as key regulators of intercellular communication and tissue regeneration.
Exosomes are secreted by most cell types, including platelets, which are particularly rich in regenerative mediators.
These vesicles carry messenger RNA, microRNA, and proteins that influence how recipient cells behave, controlling processes such as angiogenesis, fibroblast proliferation, collagen synthesis, and immune modulation.
Unlike traditional platelet-rich plasma (PRP), which relies primarily on soluble growth factors released after platelet activation, autologIX focuses on isolating and concentrating the exosomal fraction, where the most precise regenerative information resides.
Exosomes are not just an additive to PRP — they are the biological language through which platelets and cells orchestrate healing. autologIX is designed to extract this language from plasma — capturing the body’s own exosomes and preserving them in their natural biological environment.
By combining exosomes with their supporting plasma components (growth factors, fibrin, cytokines, and proteins), The autologIX provides a stable, potent, and reproducible autologous therapy.
Scientific Rationale
Several studies have demonstrated that exosomes derived from autologous blood components replicate and even exceed the biological effects traditionally attributed to PRP.
Their nanometric size allows them to penetrate tissue barriers, reach target cells, and regulate gene expression directly.
The regenerative process involves three key biological domains — cell signaling, matrix remodeling, and immune regulation — and exosomes act simultaneously in all three.
Signal Amplification
Exosomes function as messengers, delivering specific regulatory microRNAs and proteins that activate transcription factors in recipient cells, upregulating genes related to proliferation, angiogenesis, and collagen synthesis.
Matrix Remodeling
Exosomes stimulate fibroblasts and mesenchymal progenitor cells to rebuild organized extracellular matrix while maintaining balance between synthesis and degradation.
Immune Modulation
By influencing macrophage polarization and cytokine release, exosomes reduce pro-inflammatory signaling and promote resolution of inflammation, creating a microenvironment suitable for repair.
The autologIX replicates this physiology in a clinical setting by concentrating exosomes in a plasma fraction that retains the necessary co-factors for stability and function — a “biological microenvironment” that mirrors how exosomes act inside the body.
Preparation of
The procedure begins with a 48 mL blood draw divided into four 12 mL sterile tubes designed specifically for regenerative preparation.
Each tube contains a separation gel and anticoagulant that preserve platelet structure and ensure clear plasma separation.
After centrifugation, the upper platelet-rich plasma (PRP) layer is collected. This plasma contains a mixture of platelets, soluble proteins, and exosomes that circulate naturally in the bloodstream.
It forms the biological base for the autologIX process, which concentrates and refines this fraction into a standardized exosome-rich preparation.
Because the procedure uses only the patient’s own blood, the final product remains 100 % autologous — ensuring compatibility, safety, and stability without any additives or foreign substances.
AutologIX Advantages
8
MIN
Process Time
100%
AUTOLOGOUS
95%
SUCCESS RATE
ProtSmart 6
At the core of autologIX lies the ProtSmart 6 ultrafiltration device — a precision system that separates plasma components according to molecular size, selectively retaining the exosomal and protein-rich fraction.
REGENERATIVE FACTOR STRUCTURE INSIDE THE PROTSMART 6 FILTER
MULTI-TUBE STRUCTURE FOR PRECISE ACTIVATION
800 Tubes
CROSS-SECTIONAL STRUCTURE OF THE HOLLOW FIBER FILTER
MEDISULFONE UF SEM IMAGE
(COXEM, EM30AX 300X)
ULTRAFILTRATION TECHNOLOGY OF PROTSMART 6
Use of high-precision ultrafiltration filter (≤ 5nm)
Preservation of only effective components above 15 kDa
Removal of unnecessary moisture, salts, and anticoagulants, etc.
Technical Specifications:
- Filtration cut-off: 15 kDa
- Average pore diameter: ≤ 5 nm
- Process time: ≈ 8 minutes
- Input plasma: 4 × 12 mL tubes (≈ 48 mL total)
- Output: ≈ 6–7 mL exosome-rich autologous plasma concentrate
The hollow-fiber ultrafiltration membrane allows small molecules (water, salts, and anticoagulants) to pass through while retaining larger components — exosomes, platelets, fibrin fragments, cytokines, and proteins.
A gentle pressure gradient and low-shear conditions protect the vesicles from rupture or degradation.
During centrifugation, platelets are a ctivated in a controlled manner, releasing additional exosomes and growth factors into the retained plasma.
The process yields a homogeneous concentrate with a high density of exosomes expressing surface markers CD9, CD63, and CD81, confirming their extracellular vesicle origin.
This technology bridges two critical needs in regenerative medicine — biological potency and standardization.
It enables the reproducible preparation of an autologous exosome concentrate that maintains biological integrity and consistency across treatments.
